Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementationKristine A. Frerichs, Niels W.C.J. van de Donk, Alfredo Perales‐Puchalt et al.|Blood Advances|2023Cited by 85
Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1.Niels W.C.J. van de Donk, María‐Victoria Mateos, Alfred L. Garfall et al.|Journal of Clinical Oncology|2023Cited by 28
P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTSKristine A. Frerichs, Niels W.C.J. van de Donk, Christie P.M. Verkleij et al.|HemaSphere|2023Cited by 5
P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1Niels W.C.J. van de Donk, María‐Victoria Mateos, Alfred L. Garfall et al.|HemaSphere|2023Cited by 5